Hematologist
CION Cancer Clinics
Glofitamab for relapsed DLBCL: how the bispecific antibody works | CION Cancer Clinics
Glofitamab is a bispecific antibody used mainly for DLBCL that has come back after two or more treatments, including after CAR-T. It links your T cells to lymphoma cells so they can attack them. Being ready-made, it starts without a manufacturing wait. The early doses need close watching for immune reactions. This page explains the course, who it suits and what to ask. At CION Cancer Clinics, our haematology team plans myeloma and lymphoma care with you, discussed at a tumour board and explained in plain words.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What is glofitamab, and when is it used in DLBCL?
- What does a course of glofitamab look like?
- Who is glofitamab suited to, and who is it not?
- What do the words in the treatment plan mean?
- What do families often misunderstand about bispecific antibodies?
- What can this page not tell you, and what should you ask?
- Common questions about glofitamab in DLBCL
The short answer
What is glofitamab, and when is it used in DLBCL?
Glofitamab is a bispecific antibody: a drip medicine that grabs a lymphoma cell with one arm and one of your own T cells with the other, so the T cell can attack the lymphoma. It is mainly used for DLBCL that has come back or not responded after two or more earlier treatments.
How it differs from CAR-T
Both use your T cells against the lymphoma. CAR-T changes your cells in a laboratory, which takes weeks. Glofitamab is ready-made, so it can start without that wait. It is given as a set course of drips rather than one infusion, and the early doses are watched closely.
Why the doses start small
The first time T cells are switched on against lymphoma, the immune system can react strongly. To lower that risk, the course begins with smaller step-up doses, and a single drip of another antibody, obinutuzumab, is usually given a week before to reduce the number of B cells. Your team sets every dose. This page gives none.
What this page covers
This page is about glofitamab in relapsed DLBCL. For how bispecific antibodies work across all lymphoma types, see the broader bispecific guide linked below.
The course
What does a course of glofitamab look like?
Details differ between centres. This is the usual shape.
-
Assessment
A recent biopsy and scan, blood tests, and checks for infections such as hepatitis B, which can flare when B cells are lowered.
-
Pre-treatment drip
A single drip of obinutuzumab, usually a week before the first glofitamab dose, to reduce the number of B cells in the blood.
-
Step-up doses with close watching
The first doses are smaller. The first dose, and sometimes the next, is given with an overnight hospital stay so a reaction can be treated quickly.
-
The rest of the course
Full doses are then given as day-care drips at regular intervals for a fixed number of cycles. It is not continued indefinitely.
-
Scans during and after
PET-CT scans check the response. Your team decides what follow-up looks like once the course is complete, including blood tests and checks for infection, because the immune system takes time to recover after the last dose.
Not sure whether this applies to you?
Ask an oncologistWeighing it up
Who is glofitamab suited to, and who is it not?
Often considered for
Adults whose DLBCL has come back after two or more lines of treatment, including people who relapsed after CAR-T or who could not have CAR-T. They need to be well enough to manage the early hospital stays and to have a family member who can watch for warning signs.
People who cannot wait for CAR-T
Because it is ready-made, it can suit someone whose lymphoma is growing and who cannot wait weeks for cells to be manufactured, or who cannot travel to a CAR-T centre.
Often not suited to
The team thinks carefully before using it in some situations.
Such as
- Active, uncontrolled infection
- Lymphoma in the brain
- Lymphoma that no longer carries CD20
- Serious heart or lung illness
As an earlier treatment
Glofitamab combined with chemotherapy is being used earlier in some countries, and approvals differ. Ask whether that applies to your situation and whether a clinical trial is open.
!
One thing that cannot wait
After any dose, especially the early ones, a fever, shivering, dizziness, breathlessness, new confusion, trouble speaking or unusual sleepiness needs same-day help. These can be signs of cytokine release syndrome or a nerve reaction. Call the treating team's emergency number, or go to the nearest emergency department or call 108, and say the person is on a bispecific antibody.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
On your plan
What do the words in the treatment plan mean?
- Bispecific antibody
- A medicine that holds on to two different targets at once, here a lymphoma cell and a T cell.
- CD20 and CD3
- Markers on the surface of cells. CD20 sits on B cells and most DLBCL cells; CD3 sits on T cells.
- Step-up dosing
- Starting with smaller doses and building up, to lower the chance of a strong immune reaction.
- Cytokine release syndrome (CRS)
- A body-wide immune reaction, often with fever, sometimes with low blood pressure or breathlessness.
- ICANS
- A nerve reaction to immune treatments, which can cause confusion, trouble speaking or shaking.
Commonly believed
What do families often misunderstand about bispecific antibodies?
"It is the same as rituximab, which already stopped working."
Both recognise CD20, but they work differently. Rituximab marks lymphoma cells for the immune system. Glofitamab physically brings T cells to them. It can work even when the lymphoma no longer responds to rituximab-based treatment.
"It is a mild drip, so we can go home straight away."
The early doses can trigger strong immune reactions, which is why an overnight stay is usual at the start. Later doses are usually easier, but the family still needs to know the warning signs and whom to call.
"If CAR-T did not work, nothing else will."
Bispecific antibodies were studied in people whose lymphoma came back after CAR-T, and some of them responded. It is a real option at that point, not a last gesture.
"Chemotherapy side effects will be the same."
Hair loss and sickness are less typical. The effects to watch are different: immune reactions, low blood counts and infections, including chest infections, which can be serious.
Being straight with you
What can this page not tell you, and what should you ask?
This page cannot tell you whether glofitamab will work for you, how long a response might last, or what your outlook is. Those depend on how many treatments came before, how the lymphoma behaved, your fitness, and results from your own biopsy and scans. The studies so far are mostly in people with several earlier treatments.
Access and cost in India
Availability in India is limited and can change as approvals and import rules change. It is an expensive medicine, and cover under Aarogyasri, PM-JAY, CGHS, ECHS, EHS or insurance is uncertain. Ask for a written estimate and check current scheme rules before you commit.
Questions worth asking
Ask where the early doses will be given and how long the overnight stays are. Ask what infections you are being protected against, whom to call at night, and what happens if the lymphoma does not respond. Ask whether CAR-T or a clinical trial should be considered first.
How CION helps
CION's haematology team reviews your records, discusses the case at a tumour board, explains where a bispecific antibody fits among your options and coordinates care with qualified centres.
Questions we are asked
Common questions about glofitamab in DLBCL
Is glofitamab given as an injection or a drip?
Glofitamab is given as a drip into a vein. The early doses are given with close watching, often with an overnight stay, and later doses are usually day-care visits. Other bispecific antibodies may be given differently, and your team will explain the schedule for the one chosen.
Why does my father need a different drip a week before?
That drip, obinutuzumab, lowers the number of B cells in the blood before glofitamab starts. Fewer B cells means a smaller immune reaction to the first dose. It is part of the plan, not an extra treatment for something else. Ask the team if you are unsure of the date.
How long does the treatment go on?
Glofitamab is given as a fixed course over some months, not continued indefinitely. The team may stop earlier if the lymphoma grows or side effects are too heavy. Your haematologist will tell you the planned length and how the response will be checked.
What are the most common side effects?
Cytokine release syndrome, mostly after early doses, is the most common. Low blood counts, infections, tiredness, rash and fever also occur. Nerve reactions are less common. The team will check blood tests before doses and give you a card listing warning signs.
Can it be used after CAR-T has failed?
Yes. It has been studied in people whose DLBCL came back after CAR-T, and some responded. It is also used for people who could not have CAR-T. Whether it suits you depends on your fitness, your recent biopsy and scan, and access.
Do we need precautions against infection at home?
Yes. B cells and some antibodies stay low for a long time, so infections are more likely. The team may give preventive medicines and check for hepatitis B. Avoid close contact with people who are ill, and report a fever or cough early.
Is glofitamab covered by Aarogyasri or insurance?
Cover is uncertain and varies. Some insurance policies may include it as an advanced treatment, often with limits, and scheme cover for newer medicines is limited. Ask the treating centre's insurance desk to confirm your current scheme or policy terms in writing.
Can CION help us decide whether this is the right next step?
Yes. Bring every biopsy and PET report and a list of earlier treatments with dates. CION's haematology team reviews them, discusses the case at a tumour board and explains how bispecific antibodies, CAR-T and trials compare for you, then coordinates care.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- NICE — Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)
- National Cancer Institute — Adult Non-Hodgkin Lymphoma Treatment (PDQ) - Health Professional Version
- Leukemia & Lymphoma Society — Non-Hodgkin Lymphoma
- Cancer Research UK — Non-Hodgkin lymphoma
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Bispecific antibodies in lymphomaHow bispecific antibodies work across all lymphoma typesCAR-T in Second-Line DLBCLThe cell therapy often used before a bispecificSalvage Chemotherapy and Autologous Transplant in DLBCLThe other second-line routeAggressive B-Cell LymphomaThe overview of this lymphoma group
Talk to us
Lymphoma back after several treatments?
Share the biopsy and scan reports. CION's haematology team will review them and explain where the newer options fit. One helpline serves every CION centre.